Study guide
Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics
EBP-EAP Examination in Paediatrics Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding
EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)
2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity
Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol
3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections
Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening
4 Chapter 4: Acute Paediatric Emergencies & Critical Care
EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination
5 Chapter 5: Paediatric Respiratory Medicine
Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations
6 Chapter 6: Paediatric Cardiology
Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever
7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition
Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure
8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance
Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management
9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism
Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)
10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health
Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy
11 Chapter 11: Paediatric Haematology & Oncology
Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia
12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy
Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules
13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions
The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia
14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics
Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics
15 Chapter 15: Paediatric Ophthalmology & ENT Disorders
Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions
16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health
Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance
17 Chapter 17: Adolescent Medicine & Healthcare Transition
Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition
18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics
Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics
19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine
Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy
Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics
Key Takeaways Explain This Topic AI
Clinical research architectures are stratified into observational designs (cross-sectional, case-control, cohort) and experimental designs (randomised controlled trials, cluster RCTs, crossover trials), selected according to disease rarity, exposure frequency, latency, ethical boundaries, and required inferential strength.
The Bradford Hill criteria (temporality, strength of association, biological gradient, consistency, plausibility, coherence, specificity, experiment, analogy) evaluate causal relationships, with temporality representing the sole absolute prerequisite.
Systematic biases—encompassing selection bias (e.g., Berkson's admission bias), information bias (e.g., differential recall bias in retrospective parent interviews, detection bias), attrition bias, and publication bias—compromise internal validity and cannot be corrected by increasing sample size.
Confounding occurs when an extraneous factor is independently associated with the exposure and an independent risk factor for the outcome without lying on the causal pathway; it is controlled in study design (randomisation, restriction, matching) or analysis (stratification, multivariable regression), whereas effect modification denotes different effects across subgroups on a specified scale and should be reported with uncertainty.
Measures of disease frequency (incidence rate, cumulative incidence, point and period prevalence) and association (relative risk, odds ratio with the rare disease assumption, absolute risk reduction, number needed to treat N N T = 1 / A R R NNT = 1/ARR NNT = 1/ A RR , and number needed to harm N N H = 1 / A R I NNH = 1/ARI NN H = 1/ A R I ) provide the mathematical foundation for evaluating paediatric therapeutic and preventive interventions.
Last updated: November 2026
Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics
In contemporary paediatric practice, clinical decision-making must be anchored on rigorous methodological appraisal of scientific evidence. Paediatricians frequently encounter clinical trials evaluating novel biologic agents, epidemiological cohorts investigating environmental determinants of childhood illness, and diagnostic evaluations of rapid bedside assays. Deciphering this medical literature requires a comprehensive understanding of study architectures, the causal inference framework, mechanisms of systematic bias, and the quantitative metrics that define disease frequency and therapeutic efficacy.
Hierarchy of Evidence and Study Architectures
Clinical study designs are broadly divided into observational and experimental architectures, depending on whether the investigator actively assigns an intervention or passively monitors naturally occurring exposures. [Clinical Research Designs]
- |
- +---------------------------+---------------------------+
- | |
- [Observational] [Experimental]
- | |
- +-----------+-----------+ +-----------+-----------+
- | | | | | |
- [Cross- [Case- [Cohort] [Parallel [Cluster [Crossover
- Sectional] Control] (Prospective / RCT] RCT] Trial]
- (Prevalence)(Odds Ratio) Retrospective, RR)
- Observational Study Architectures
Cross-Sectional Studies (Prevalence Studies) :
Design : Exposure status and disease outcome are measured simultaneously in a defined population at a single cross-section in time ("snapshot").
Utility : Excellent for estimating disease burden, point prevalence, and healthcare resource allocation (e.g., assessing the prevalence of childhood asthma and passive tobacco smoke exposure in school-age children).
Limitation : Because exposure and outcome are assessed concurrently, cross-sectional studies cannot establish temporal sequence (i.e., whether the exposure preceded the disease). They are also subject to prevalence-incidence bias (Neyman bias), disproportionately identifying chronic, long-duration indolent cases over rapidly fatal or transient illnesses.
Case-Control Studies :
Design : Observational, retrospective architecture that identifies subjects based on outcome status (cases with the disease vs controls without the disease) and looks backward in time to determine the frequency or odds of prior exposure.
Utility : The gold standard design for investigating rare diseases (e.g., Kawasaki disease, pediatric hepatocellular carcinoma, Reye syndrome) or conditions with prolonged latency periods. They are fast, inexpensive, and require relatively small sample sizes.
Metric of Association : Because the investigator artificially fixes the ratio of cases to controls (e.g., 1:1 or 1:4), true population disease incidence cannot be calculated. Thus, Relative Risk (Risk Ratio) cannot be directly determined ; the Odds Ratio (OR) is the sole mathematically valid measure of association.
Limitations : Highly susceptible to selection bias in choosing control groups and differential recall bias , as parents of affected children scrutinize and remember historical exposures far more meticulously than parents of healthy controls.
Cohort Studies (Prospective and Retrospective) :
Design : Subjects are identified based on their exposure status (exposed vs unexposed cohorts), confirmed to be free of the outcome of interest at baseline, and followed over time to observe the development of incident disease.
Prospective Cohort : The exposure is measured at study inception, and participants are followed forward in time into the future (e.g., following a birth cohort of very-low-birth-weight preterm infants to assess neurodevelopmental outcomes at age 5).
Retrospective (Historical) Cohort : The exposure and outcome have both already occurred at the start of the study, but the cohort is assembled using historical baseline records (e.g., neonatal intensive care records from 2010 to 2020) and tracked forward through the records to calculate disease occurrence.
Utility : The optimal design for assessing rare exposures (e.g., in utero valproate exposure), establishing true temporal precedence, and measuring true incidence rates , cumulative incidence , and Risk Ratios (Relative Risk) .
Limitations : Expensive, time-consuming, inefficient for rare diseases, and vulnerable to attrition bias from differential loss to follow-up over prolonged observation periods.
Experimental Study Architectures
Randomised Controlled Trials (RCTs) :
Design : The prospective experimental gold standard where participants are allocated randomly into intervention or control arms, balancing known and unknown prognostic factors in expectation, although chance baseline imbalances remain possible.
Parallel-Group RCT : Participants are randomised to receive either treatment A or treatment B and followed concurrently.
Blinding (Masking) : Open-label (no blinding), single-blind (participants unaware), double-blind (participants and treating investigators/outcome assessors unaware), and triple-blind (participants, investigators, and data monitoring/statistical analysts unaware).
Cluster Randomised Controlled Trials :
Design : Intact groups of individuals (clusters)—such as whole paediatric primary care clinics, hospital wards, schools, or neonatal intensive care units (NICUs)—are randomised rather than individual patients.
Indications : Indicated when an intervention naturally operates at a collective level (e.g., a hand-hygiene hospital campaign, school nutrition curriculum) or when individual randomisation would lead to substantial contamination (where control participants inadvertently adopt aspects of the intervention from treated peers nearby).
Methodological Considerations : Observations within the same cluster are correlated (not statistically independent). Analysts must account for the Intracluster Correlation Coefficient (ICC) ; failing to adjust for clustering results in spuriously narrow confidence intervals and inflated Type I error rates.
Crossover Trials :
Design : Each participant receives two or more interventions in sequential succession in a randomised order, acting as their own internal control.
Washout Period : A mandatory interval between treatment phases to ensure that the pharmacological or biological effects of the first intervention completely disappear before the second intervention begins.
Indications and Contraindications : Highly efficient for chronic, stable conditions with constant symptom levels (e.g., stable cystic fibrosis, maintenance therapy in mild persistent asthma, attention-deficit hyperactivity disorder). Strictly contraindicated in acute, curable, or rapidly evolving illnesses (e.g., acute neonatal sepsis, bacterial meningitis) because the patient's clinical baseline is irreversibly altered after the initial phase.
Study Design Directionality Temporal Sequence Established? Primary Measure of Association Primary Strength Principal Vulnerability
Cross-Sectional Snapshot at a single point No (simultaneous assessment) Prevalence Ratio / Odds Ratio Fast, low cost, defines public health prevalence Cannot establish causality; prevalence-incidence bias
Case-Control Retrospective (Outcome → \rightarrow → Exposure) Yes, historically Odds Ratio ( O R OR OR ) Ideal for rare paediatric diseases and long latencies High risk of recall bias and inappropriate control selection
Cohort (Prospective) Prospective (Exposure → \rightarrow → Outcome) Yes (robustly established) Risk Ratio ( R R RR RR ) / Rate Ratio Ideal for rare exposures; direct measurement of incidence High cost, prolonged duration, loss to follow-up (attrition)
Parallel RCT Prospective experimental Yes Risk Ratio ( R R RR RR ), ARR, NNT Rigorous causal inference; balances known/unknown confounders in expectation High cost, ethical constraints, limited external generalisability
Cluster RCT Group-level prospective experimental Yes Risk Ratio ( R R RR RR ), adjusted for ICC Prevents contamination; evaluates system/school interventions Requires larger sample sizes; complex intracluster analysis
Crossover RCT Within-patient sequential Yes Within-subject mean difference / RR High statistical efficiency; eliminates inter-subject variance Carry-over effects; only suitable for stable chronic conditions
Establishing Causality: The Bradford Hill Framework
A fundamental dictum of clinical biostatistics is that association does not prove causation . An observed statistical correlation between an environmental exposure and a paediatric disease may arise from chance, methodological bias, or confounding. In 1965, Sir Austin Bradford Hill formulated nine criteria to aid epidemiologists in assessing whether an observed statistical association is truly causal. [Bradford Hill Causality Criteria]
- |
- +-------------------+---------------+-------------------+-------------------+
- | | | | |
- [Temporality] [Strength] [Biological Gradient] [Consistency] [Plausibility &
- *MANDATORY* (High RR/OR) (Dose-Response) (Replicated across Coherence]
- (Exposure precedes diverse cohorts) (Matches biology
- outcome) & pathology)
Temporality (The Sole Absolute Prerequisite) :
The exposure must indisputably precede the occurrence of the disease outcome in chronological time.
Paediatric Example : In evaluating maternal antibiotic administration and the subsequent development of childhood atopic asthma, researchers must rigorously confirm that maternal antibiotics occurred prior to child wheezing episodes, rather than antibiotics being administered in infancy for early prodromal asthma wheezing misdiagnosed as bronchitis.
Strength of Association :
The larger the relative risk or odds ratio, the less likely the association is entirely attributable to subtle, unmeasured confounding.
Paediatric Example : The initial epidemiological demonstration that the prone sleeping position increased the risk of Sudden Infant Death Syndrome (SIDS) with an adjusted odds ratio exceeding 8.0 8.0 8.0 to 10.0 10.0 10.0 represented a massive association unlikely to be explained by residual confounding.
Biological Gradient (Dose-Response Relationship) :
Greater levels or duration of exposure lead to a progressively higher incidence or severity of the disease.
Paediatric Example : Progressive increase in childhood asthma exacerbations and hospitalisations in proportion to the number of cigarettes smoked daily by cohabiting parents.
Consistency :
The association is repeatedly and independently observed across different geographic regions, investigators, study designs, and patient demographic subgroups.
Paediatric Example : The association between congenital rubella virus infection and the congenital rubella syndrome triad (sensorineural deafness, cataracts, cardiac malformations) verified across global populations.
Biological Plausibility :
The proposed association is biologically explainable based on existing pathophysiological, cellular, genetic, or immunological knowledge.
Paediatric Example : Maternal folate deficiency causing neural tube defects is biologically plausible because folate is an indispensable one-carbon donor co-factor for pyrimidine and purine synthesis during early embryological neural fold closure.
Coherence :
The causal interpretation does not conflict with the known natural history, epidemiology, and biology of the disease.
Specificity :
A single specific exposure leads to a single distinct outcome. Considered the weakest of Bradford Hill's criteria in contemporary medicine because most paediatric illnesses (e.g., cerebral palsy, failure to thrive) have complex multifactorial etiologies.
Experimental Evidence :
When an intervention removes or reduces the exposure in a controlled environment, the frequency of the disease declines.
Paediatric Example : After the US "Back to Sleep" campaign began in 1994, SIDS rates declined by more than 50 % 50\% 50% over subsequent years. This population-level change supports the benefits of supine sleep advice.
Analogy :
The observed relationship parallels previously established causal phenomena. For instance, knowing that thalidomide causes severe limb phocomelia during organogenesis increases biological receptivity to other pharmaceutical teratogens acting during the first trimester.
Bias in Paediatric Research: Classification and Mitigation
Bias is any systematic error in the design, conduct, analysis, or dissemination of a study that results in a distorted estimate of an association or treatment effect. Unlike random error—which reflects unpredictable sampling variability and decreases as sample size grows— systematic bias cannot be reduced or corrected by increasing the sample size . [Systematic Biases]
- |
- +-------------------+-------------+-------------+-------------------+
- | | | |
- [Selection Bias] [Information Bias] [Attrition Bias] [Publication Bias]
- Berkson's Bias - Recall Bias (Parent report)- Differential - Selective positive
- Volunteer Bias - Detection/Observer Bias dropout in trials journal reporting
- Healthy Child - Misclassification Bias - ITT plus missing- - Solution: Clinical
- data methods trial registries
- 1. Selection Bias
Selection bias occurs when the method of selecting participants creates a systematic difference between the study sample and the target source population, or between comparison arms.
Berkson's Bias (Admission Rate Bias) : Occurs in hospital-based case-control studies when cases and controls are recruited from tertiary inpatient populations. Because hospitalised children have a higher probability of multiple concurrent morbidities than non-hospitalised community children, spurious associations emerge between two completely unrelated diseases.
Healthy Child / Healthy Worker Effect : Enrolling participants from organised childcare or sports programs preferentially recruits healthier children, underestimating true community disease rates.
Non-Response / Volunteer Bias : Individuals who volunteer for clinical trials or return surveys often have different health literacy, socioeconomic status, and health-seeking behaviours than non-respondents.
2. Information (Measurement) Bias
Information bias arises from systematic errors in collecting, reporting, measuring, or recording exposure or outcome data.
Recall Bias : Differential recollection of past exposures between subjects with disease and subjects without disease. A mother whose infant was born with hypoplastic left heart syndrome will spend hours obsessively searching her memory and over-reporting minor periconceptional medications, viral illnesses, or environmental exposures, whereas a mother of a healthy infant will forget similar transient events. Mitigation : Utilize prospectively recorded medical registries, pharmacy dispensing databases, or blind interviewers and participants to the study hypothesis.
Detection Bias (Surveillance Bias) : When exposed participants are monitored more intensively than unexposed individuals, subclinical or mild disease outcomes are detected far more frequently in the exposed group.
Observer / Interviewer Bias : An unblinded investigator who knows the child's treatment allocation unconsciously assesses or records clinical endpoints differently (e.g., rating lung sounds as "clearer" in a child known to receive active inhaled bronchodilator therapy).
3. Attrition Bias
Attrition bias occurs when participants drop out of a longitudinal cohort or trial differentially between study groups. For example, if children experiencing adverse medication side effects systematically withdraw from the active treatment arm, analyzing only the patients who successfully complete the protocol (a per-protocol analysis ) artificially inflates the drug's apparent tolerability and efficacy.
Mitigation: Intention-to-Treat (ITT) Analysis : Every randomised participant is analyzed within the group to which they were originally assigned, regardless of non-compliance, protocol deviations, or withdrawal. ITT preserves randomised assignment when estimating the effect of allocation. It does not recover missing outcomes: continue follow-up where possible, use appropriate missing-data methods, and test sensitivity to their assumptions.
4. Publication Bias
Investigators and journal editors are significantly more inclined to submit and publish trials that report positive, statistically significant, or striking results than studies showing null or negative outcomes. Consequently, published literature often overestimates true treatment benefits. Mitigation : Mandatory prospective registration of all clinical trials in public registries (e.g., ClinicalTrials.gov, the public EU Clinical Trials Information System [CTIS]) prior to patient enrollment.
- Confounding and Effect Modification
- Confounding
A confounder is an extraneous variable that distorts the apparent mathematical association between an exposure and an outcome. To be a true confounder, a variable must fulfill three strict criteria:
It must be independently associated with the exposure (differentially distributed among exposed and unexposed).
It must be an independent risk factor or cause of the outcome , occurring even in the absence of the exposure.
It must NOT lie on the causal pathway between the exposure and the outcome (i.e., it must not be a biological intermediate). [Confounder (Z)]
- (e.g., Maternal Smoking)
- / \
- / \
- Associated / \ Independent
- with Exposure / \ Risk Factor
- v v
- [Exposure (X)] --------> [Outcome (Y)]
- (Maternal Caffeine) (Low Birth Weight)
- Assess after
- adjustment
Hypothetical Paediatric Example : Suppose an observational study observes that heavy maternal caffeine intake during pregnancy is associated with low infant birth weight ( O R = 1.8 OR = 1.8 OR = 1.8 ). However, mothers who consume high amounts of caffeine are also significantly more likely to smoke cigarettes. Maternal cigarette smoking is strongly associated with caffeine consumption (Criterion 1), is an established independent cause of fetal growth restriction and low birth weight (Criterion 2), and is not an intermediate biological step caused by caffeine (Criterion 3). Suppose the association vanishes after adequate smoking adjustment in these illustrative data: this supports confounding by smoking. This example does not establish that caffeine has no independent effect on fetal growth.
Methods of Controlling Confounding
Confounding can be prevented during study design or adjusted for during statistical analysis:
Phase Method Mechanism and Paediatric Application Limitations
Design Randomisation Random assignment balances measured and unmeasured confounders in expectation; chance imbalance can remain Only feasible in experimental RCTs; ethical limits
Design Restriction Eliminates confounders by limiting eligibility to a homogeneous group (e.g., restricting trial to non-smokers) Reduces study generalisability (external validity)
Design Matching Selecting controls that share identical confounding features with cases (e.g., matching by age, gestational age, sex) Complex recruitment; cannot evaluate matched variable
Analysis Stratification Calculating associations separately within strata of the confounder (e.g., Mantel-Haenszel pooled OR) Impractical when managing multiple confounders simultaneously
Analysis Multivariable Regression Mathematical modeling (linear, logistic, Cox) that estimates the effect of exposure while holding other covariates constant Requires large sample sizes; cannot adjust for unmeasured variables
Effect Modification (Interaction)
Effect modification is fundamentally different from confounding. Confounding is a methodological distortion that creates a false association or masks a true one, which the investigator seeks to remove. In contrast, effect modification means that the exposure–outcome association differs across subgroups on a specified effect scale. It may have a biological explanation, but a statistical interaction alone does not establish one.
Paediatric Example : An inhaled steroid trial demonstrates a massive reduction in asthma hospitalisations among children with allergic eosinophilic asthma ( R R = 0.35 RR = 0.35 RR = 0.35 ), but shows zero benefit among children with non-atopic viral wheeze ( R R = 0.98 RR = 0.98 RR = 0.98 ).
Identification : Compare subgroup estimates and confidence intervals, preferably using a pre-specified interaction test. Modification can differ on absolute and relative scales. Report relevant subgroup effects and their uncertainty; a pooled average alone can conceal clinically important differences.
Quantitative Measures of Disease Frequency and Association
Epidemiological measures quantify the frequency of disease in populations and the comparative magnitude of risk between groups.
Measures of Disease Frequency
Prevalence :
The proportion of a defined population that has a disease at a specific point or period in time. Prevalence = Number of existing disease cases at a specified time Total population at that specified time \text{Prevalence} = \frac{\text{Number of existing disease cases at a specified time}}{\text{Total population at that specified time}} Prevalence = Total population at that specified time Number of existing disease cases at a specified time
Point Prevalence : Assessed at a single calendar moment (e.g., proportion of children with active wheeze on October 1st).
Period Prevalence : Assessed over an interval of time (e.g., proportion of adolescents reporting an episode of major depression during 2026).
Incidence :
Quantifies the occurrence of new incident cases of disease arising in a population initially at risk over a specified time.
Cumulative Incidence (Incidence Proportion / Attack Rate) : Assumes a closed population followed over a fixed duration. Cumulative Incidence = Number of new cases occurring during follow-up period Total population at risk at baseline free of disease \text{Cumulative Incidence} = \frac{\text{Number of new cases occurring during follow-up period}}{\text{Total population at risk at baseline free of disease}} Cumulative Incidence = Total population at risk at baseline free of disease Number of new cases occurring during follow-up period
Incidence Rate (Incidence Density) : Measures the speed of new case occurrence per unit of dynamic person-time, ideal for open cohorts with varying follow-up periods. Incidence Rate = Number of new cases occurring during observation Total person-time at risk contributed by all individuals \text{Incidence Rate} = \frac{\text{Number of new cases occurring during observation}}{\text{Total person-time at risk contributed by all individuals}} Incidence Rate = Total person-time at risk contributed by all individuals Number of new cases occurring during observation
Relationship for Stable Diseases : When disease incidence and duration are stable and prevalence is low ( < 10 % <10\% < 10% ): Prevalence ≈ Incidence Rate × Average Disease Duration \text{Prevalence} \approx \text{Incidence Rate} \times \text{Average Disease Duration} Prevalence ≈ Incidence Rate × Average Disease Duration Thus, an effective medical therapy that prolongs child survival without curing the disease (e.g., cystic fibrosis transmembrane conductance regulator modulators in CF) will increase disease prevalence even if incidence remains constant.
The Standard 2x2 Contingency Table
- Exposure Status Developed Disease (Cases) Remained Healthy (Controls) Total Group
- Exposed Group a a a (True Positive / Exposed Cases) b b b (Exposed Non-Cases) a + b a + b a + b
- Unexposed Group c c c (Unexposed Cases) d d d (Unexposed Non-Cases) c + d c + d c + d
- Total a + c a + c a + c b + d b + d b + d a + b + c + d a + b + c + d a + b + c + d
- Experimental / Exposed Event Rate ( E E R EER EER ) = a a + b = \frac{a}{a + b} = a + b a
- Control / Unexposed Event Rate ( C E R CER CER ) = c c + d = \frac{c}{c + d} = c + d c
- Measures of Association and Clinical Effect Sizes
Risk Ratio (Relative Risk, R R RR RR ) :
The ratio of disease incidence in the exposed group to disease incidence in the unexposed group. Calculated directly in prospective cohort studies and RCTs. R R = E E R C E R = a / ( a + b ) c / ( c + d ) RR = \frac{EER}{CER} = \frac{a / (a + b)}{c / (c + d)} RR = CER EER = c / ( c + d ) a / ( a + b )
Interpretation : R R = 1.0 RR = 1.0 RR = 1.0 indicates no association; R R > 1.0 RR > 1.0 RR > 1.0 indicates increased risk (harmful exposure); R R < 1.0 RR < 1.0 RR < 1.0 indicates decreased risk (protective intervention).
Odds Ratio ( O R OR OR ) :
The ratio of the odds of exposure among cases to the odds of exposure among controls. The primary metric in case-control studies. O R = Odds of exposure in cases Odds of exposure in controls = a / c b / d = a × d b × c OR = \frac{\text{Odds of exposure in cases}}{\text{Odds of exposure in controls}} = \frac{a / c}{b / d} = \frac{a \times d}{b \times c} OR = Odds of exposure in controls Odds of exposure in cases = b / d a / c = b × c a × d
The Rare Disease Assumption : When outcome risks are low in both exposed and unexposed source-population groups (often < 5 % <5\% < 5% to 10 % 10\% 10% ), O R ≈ R R OR \approx RR OR ≈ RR . The chosen case-to-control ratio in a case-control sample does not determine these risks. With common outcomes, the OR generally lies farther from 1 than the RR, in either the harmful or protective direction.
Absolute Risk Reduction ( A R R ARR A RR ) :
The arithmetic difference in event rates between control and experimental groups. A R R = C E R − E E R ARR = CER - EER A RR = CER − EER For an adverse outcome, a positive ARR indicates benefit; a negative value indicates increased risk.
Relative Risk Reduction ( R R R RRR RRR ) :
The proportion of baseline risk eliminated by the intervention. R R R = C E R − E E R C E R = 1 − R R RRR = \frac{CER - EER}{CER} = 1 - RR RRR = CER CER − EER = 1 − RR
Number Needed to Treat ( N N T NNT NNT ) :
The number of paediatric patients who must receive the active intervention over a specific timeframe to prevent one additional adverse outcome. N N T = ⌈ 1 A R R ⌉ ( A R R > 0 ) NNT = \left\lceil \frac{1}{ARR} \right\rceil \quad (ARR > 0) NNT = ⌈ A RR 1 ⌉ ( A RR > 0 ) If adverse-event risk rises, calculate ARI and NNH instead; zero risk difference has no finite NNT. (Always rounded up to the nearest integer; reported with its duration of treatment) .
Absolute Risk Increase ( A R I ARI A R I ) and Number Needed to Harm ( N N H NNH NN H ) :
For adverse events or adverse exposures where E E R > C E R EER > CER EER > CER : A R I = ∣ E E R − C E R ∣ ARI = |EER - CER| A R I = ∣ EER − CER ∣ N N H = ⌈ 1 A R I ⌉ ( A R I > 0 ) NNH = \left\lceil \frac{1}{ARI} \right\rceil \quad (ARI > 0) NN H = ⌈ A R I 1 ⌉ ( A R I > 0 ) (Using the Cochrane convention, round upward to a whole number for either benefit or harm; state the outcome and follow-up period) .
- Worked Clinical Paediatric Examples
- Worked Example 1: Inhaled Corticosteroid Trial in Paediatric Asthma
A randomised trial evaluates maintenance daily low-dose inhaled budesonide versus placebo over 12 months in 2,000 children with persistent asthma:
Control Group (Placebo) : 1,000 children enrolled; 150 experience a severe asthma exacerbation requiring oral steroids ( C E R = 150 / 1000 = 0.15 CER = 150 / 1000 = 0.15 CER = 150/1000 = 0.15 or 15.0 % 15.0\% 15.0% ).
Experimental Group (Budesonide) : 1,000 children enrolled; 60 experience a severe asthma exacerbation ( E E R = 60 / 1000 = 0.06 EER = 60 / 1000 = 0.06 EER = 60/1000 = 0.06 or 6.0 % 6.0\% 6.0% ).
Calculations :
Risk Ratio : R R = E E R C E R = 0.06 0.15 = 0.40 RR = \frac{EER}{CER} = \frac{0.06}{0.15} = 0.40 RR = CER EER = 0.15 0.06 = 0.40 . Children on budesonide have 40 % 40\% 40% the risk of exacerbation compared to placebo.
Relative Risk Reduction : R R R = 1 − R R = 1 − 0.40 = 0.60 RRR = 1 - RR = 1 - 0.40 = 0.60 RRR = 1 − RR = 1 − 0.40 = 0.60 ( 60.0 % 60.0\% 60.0% reduction in relative risk).
Absolute Risk Reduction : A R R = C E R − E E R = 0.15 − 0.06 = 0.09 ARR = CER - EER = 0.15 - 0.06 = 0.09 A RR = CER − EER = 0.15 − 0.06 = 0.09 ( 9.0 % 9.0\% 9.0% absolute reduction).
Number Needed to Treat : N N T = 1 A R R = 1 0.09 = 11.11 → 12 NNT = \frac{1}{ARR} = \frac{1}{0.09} = 11.11 \rightarrow 12 NNT = A RR 1 = 0.09 1 = 11.11 → 12 . Treating 12 children with daily budesonide for 12 months prevents one severe asthma exacerbation.
Worked Example 2: Observational Vaccine Effectiveness ( V E VE V E )
A prospective birth cohort follows 10,000 infants during a seasonal rotavirus outbreak:
Unvaccinated Infants : 2,000 infants; 120 contract confirmed rotavirus gastroenteritis ( C E R = 120 / 2000 = 0.06 CER = 120 / 2000 = 0.06 CER = 120/2000 = 0.06 or 6.0 % 6.0\% 6.0% ).
Vaccinated Infants : 8,000 infants; 96 contract rotavirus gastroenteritis ( E E R = 96 / 8000 = 0.012 EER = 96 / 8000 = 0.012 EER = 96/8000 = 0.012 or 1.2 % 1.2\% 1.2% ).
Calculations :
Relative Risk : R R = 0.012 0.06 = 0.20 RR = \frac{0.012}{0.06} = 0.20 RR = 0.06 0.012 = 0.20 .
Vaccine Effectiveness ( V E VE V E ) : V E = ( 1 − R R ) × 100 % = ( 1 − 0.20 ) × 100 % = 80.0 % VE = (1 - RR) \times 100\% = (1 - 0.20) \times 100\% = 80.0\% V E = ( 1 − RR ) × 100% = ( 1 − 0.20 ) × 100% = 80.0% . The unadjusted effectiveness estimate is 80 % 80\% 80% ; assess confounding and selection bias before interpreting this as causal protection.